LLY
Eli Lilly and Company
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+29/100
Last price
1,159.63
▲ 16.51 (1.44%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1,145.34
Prev close
1,143.12
Day high
1,177.07
Day low
1,139.98
Volume
2.13M
Market cap
$1.03T
P/E (TTM)
38.85
52W range
783.85 – 1,292.65
Day trading desk
Gap from prior close
+0.19%
Prior close 1,143.12
VWAP
1,154.48
+0.45% from price
Relative volume
0.88×
Normal
Session range
3.25%
1,139.98 – 1,177.06
Position in range
53%
Mid range
ATR (14D)
32.29
2.78% of price
Prior day high
1,165.73
PDH
Prior day low
1,139.50
PDL
Bid / ask spread
—
Quote not published
Session volume
2.17M
Avg 2.48M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.29%
-4.2%
1M
+0.71%
-0.4%
3M
-4.80%
-9.3%
6M
+24.32%
+6.1%
YTD
+7.71%
-6.5%
1Y
+37.82%
+21.4%
3Y
+115.50%
+33.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LLY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-306.74K
Net selling
Buy transactions
28
1.48K shares
Sell transactions
8
308.21K shares
Net transactions
+36
Buys less sells
Sell : buy shares
208.4 : 1
Heavily one-sided
Insider-held shares
1.40M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 21, 26 | SULZBERGER GABRIELLE Director |
STOCK | 4 | $4.96K | Direct |
| Sep 21, 26 | LUCIANO JUAN R Director |
STOCK | 13 | $15.92K | Direct |
| Sep 21, 26 | ALVAREZ RALPH Director |
STOCK | 10 | $12.42K | Direct |
| Sep 21, 26 | FYRWALD J. ERIK Director |
STOCK | 8 | $9.92K | Direct |
| Sep 9, 26 | SEYMOUR MELISSA Officer |
STOCK | 29 | $0 | Direct |
| Sep 2, 26 | HERNANDEZ EDGARDO Officer |
STOCK | 13 | $0 | Direct |
| Sep 2, 26 | DOZIER ERIC Officer |
STOCK | 216 | $0 | Direct |
| Aug 17, 26 | SULZBERGER GABRIELLE Director |
STOCK | 4 | $4.96K | Direct |
| Aug 17, 26 | LUCIANO JUAN R Director |
STOCK | 13 | $15.92K | Direct |
| Aug 17, 26 | JONSSON PATRIK Officer |
SELL | 6.50K | $7.64M | Direct |
| Aug 17, 26 | ALVAREZ RALPH Director |
STOCK | 10 | $12.42K | Direct |
| Aug 17, 26 | FYRWALD J. ERIK Director |
STOCK | 8 | $9.92K | Direct |
| Aug 10, 26 | ZAKROWSKI DONALD A Officer |
SELL | 2.00K | $2.37M | Direct |
| Aug 7, 26 | HAKIM ANAT General Counsel |
SELL | 5.00K | $5.95M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALVAREZ RALPH |
Director | 56.60K | Stock Award(Grant) |
FYRWALD J. ERIK |
Director | 75.54K | Stock Award(Grant) |
HAKIM ANAT |
General Counsel | — | Sale |
HERNANDEZ EDGARDO |
Officer | 46.96K | Stock Gift |
JONSSON PATRIK |
Officer | 54.78K | Sale |
LILLY ENDOWMENT, INC. |
Beneficial Owner of more than 10% of a Class of Security | 91.88M | Sale |
RICKS DAVID A |
Chief Executive Officer | 708.78K | Stock Award(Grant) |
SKOVRONSKY DANIEL |
Officer | 235.69K | Stock Award(Grant) |
VAN NAARDEN JACOB S. |
Officer | 36.27K | Stock Award(Grant) |
WHITE ANNE E |
President | 74.21K | Stock Award(Grant) |
Fundamentals
Market cap$1.03T
Enterprise value$1.08T
Revenue (TTM)$79.67B
Gross profit$66.44B
EBITDA$41.71B
Net income$26.71B
EPS (TTM)$29.79
Free cash flow$11.07B
Total cash$8.95B
Total debt$54.91B
Book value / share$38.00
Shares outstanding891.74M
Float888.95M
Short % of float0.84%
Dividend yield0.61%
Beta (5Y)0.45
Valuation & profitability ratios
Trailing P/E38.85
Forward P/E24.32
PEG ratio1.13
Price / sales—
Price / book30.46
EV / revenue13.53
EV / EBITDA25.84
Gross margin83.40%
Operating margin54.22%
Profit margin33.53%
Return on equity102.29%
Return on assets20.36%
Debt / equity162.07
Current ratio1.36
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $65.18B | $45.04B | $34.12B | $28.54B | — | +44.7% |
| Operating revenue | $65.18B | $45.04B | $34.12B | $28.54B | — | +44.7% |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | — | +31.3% |
| Gross profit | $54.13B | $36.63B | $27.04B | $21.91B | — | +47.8% |
| Research & development | $13.34B | $10.99B | $9.31B | $7.19B | — | +21.3% |
| Selling, general & admin | $11.09B | $8.59B | $7.40B | $6.44B | — | +29.1% |
| Total operating expense | $24.43B | $19.59B | $16.72B | $13.63B | — | +24.7% |
| Operating income | $29.70B | $17.04B | $10.32B | $8.28B | — | +74.3% |
| Net interest income | — | -$605.40M | -$312.30M | -$268.80M | -$314.40M | — |
| Pre-tax income | $25.73B | $12.68B | $6.55B | $6.81B | — | +102.9% |
| Tax provision | $5.09B | $2.09B | $1.31B | $561.60M | — | +143.6% |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | — | +94.9% |
| Net income to common | $20.64B | $10.59B | $5.24B | $6.24B | — | +94.9% |
| Basic EPS | 23.07 | 11.80 | 5.83 | 6.57 | — | +95.5% |
| Diluted EPS | 22.95 | 11.71 | 5.80 | 6.57 | — | +96.0% |
| EBIT | $29.70B | $17.04B | $10.32B | $7.14B | — | +74.3% |
| EBITDA | $31.69B | $18.81B | $11.85B | $8.66B | — | +68.5% |
| Basic shares | 894.80M | 897.54M | 899.38M | 950.18M | — | -0.3% |
| Diluted shares | 899.30M | 904.06M | 903.28M | 950.18M | — | -0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B | +122.4% |
| Cash & short-term investments | $7.27B | $3.27B | $2.93B | $2.21B | +122.4% |
| Accounts receivable | $17.76B | $11.01B | $9.09B | $6.90B | +61.4% |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | +81.1% |
| Total current assets | $55.63B | $32.74B | $25.73B | $18.03B | +69.9% |
| Property, plant & equipment | $24.67B | $17.10B | $12.91B | $10.14B | +44.3% |
| Goodwill & intangibles | $12.42B | $11.94B | $11.85B | $11.28B | +4.1% |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | +42.9% |
| Total current liabilities | $35.23B | $28.38B | $27.29B | $17.14B | +24.1% |
| Current debt | $1.64B | $5.12B | $6.90B | $1.50B | -68.0% |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | +43.3% |
| Total debt | $42.50B | $33.64B | $25.23B | $16.24B | +26.3% |
| Total liabilities | $85.94B | $64.44B | $53.14B | $38.71B | +33.4% |
| Retained earnings | $24.47B | $13.54B | $10.31B | $10.04B | +80.7% |
| Shareholder equity | $26.54B | $14.27B | $10.77B | $10.65B | +85.9% |
| Working capital | $20.40B | $4.36B | -$1.57B | $896.30M | +367.5% |
| Net tangible assets | $14.12B | $2.34B | -$1.07B | -$629.80M | +504.2% |
| Shares issued | 944.80M | 947.90M | 949.78M | 950.63M | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | +94.9% |
| Depreciation & amortisation | $2.00B | $1.77B | $1.53B | $1.52B | +13.0% |
| Stock-based compensation | $626.00M | $646.00M | $629.00M | $371.10M | -3.1% |
| Change in working capital | -$8.09B | -$5.38B | -$3.06B | -$800.00K | -50.3% |
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | +90.7% |
| Capital expenditure | -$10.85B | -$8.40B | -$7.39B | -$2.99B | -29.1% |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -18.0% |
| Share buybacks | -$4.11B | -$2.50B | -$750.00M | -$1.50B | -64.3% |
| Dividends paid | -$5.38B | -$4.68B | -$4.07B | -$3.54B | -15.0% |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -279.9% |
| Free cash flow | $5.96B | $414.00M | -$3.15B | $4.60B | +1,340.6% |
| End cash position | $7.27B | $3.27B | $2.82B | $2.07B | +122.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | — | +16.0% |
| Operating revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | — | +16.0% |
| Cost of revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | — | -8.6% |
| Gross profit | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | — | +21.5% |
| Research & development | $3.82B | $3.51B | $3.80B | $3.47B | $3.34B | — | +8.8% |
| Selling, general & admin | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | — | +16.9% |
| Total operating expense | $7.25B | $6.44B | $6.93B | $6.21B | $6.09B | — | +12.5% |
| Operating income | $12.46B | $9.78B | $8.99B | $8.39B | $7.02B | — | +27.4% |
| Net interest income | — | — | — | -$114.60M | -$209.00M | -$195.40M | — |
| Pre-tax income | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | — | +4.5% |
| Tax provision | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | — | +48.0% |
| Net income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | — | -4.1% |
| Net income to common | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | — | -4.1% |
| Basic EPS | 7.96 | 8.28 | 7.42 | 6.23 | 6.30 | — | -3.9% |
| Diluted EPS | 7.94 | 8.26 | 7.39 | 6.21 | 6.29 | — | -3.9% |
| EBIT | $12.46B | $9.78B | $11.56B | $7.41B | $7.02B | — | +27.4% |
| EBITDA | $12.99B | $10.29B | $12.14B | $7.88B | $7.50B | — | +26.3% |
| Basic shares | 891.50M | 893.50M | 894.80M | 895.84M | 897.90M | — | -0.2% |
| Diluted shares | 893.67M | 895.92M | 898.00M | 898.80M | 899.80M | — | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | +69.4% |
| Cash & short-term investments | $8.95B | $5.28B | $7.27B | $9.91B | $3.55B | +69.4% |
| Accounts receivable | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | +9.0% |
| Inventory | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | +15.6% |
| Total current assets | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | +17.9% |
| Property, plant & equipment | $29.29B | $26.54B | $24.67B | $22.32B | $20.53B | +10.3% |
| Goodwill & intangibles | $26.96B | $13.50B | $12.42B | $12.34B | $11.68B | +99.6% |
| Total assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | +22.1% |
| Total current liabilities | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | +30.3% |
| Current debt | $7.05B | $4.00B | $1.64B | $1.63B | $5.72B | +76.3% |
| Long-term debt | $47.86B | $39.37B | $40.87B | $40.87B | $34.18B | +21.6% |
| Total debt | $54.91B | $43.37B | $42.50B | $42.51B | $39.90B | +26.6% |
| Total liabilities | $108.40B | $85.38B | $85.94B | $91.08B | $82.57B | +27.0% |
| Retained earnings | $31.89B | $29.51B | $24.47B | $22.25B | $17.38B | +8.1% |
| Shareholder equity | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | +8.6% |
| Working capital | $16.93B | $18.20B | $20.40B | $21.93B | $10.83B | -7.0% |
| Net tangible assets | $6.92B | $17.69B | $14.12B | $11.45B | $6.59B | -60.9% |
| Shares issued | 891.50M | 943.50M | 944.80M | 946.21M | 947.20M | -5.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | -4.1% |
| Depreciation & amortisation | $534.00M | $509.00M | $585.70M | $470.30M | $478.00M | +4.9% |
| Stock-based compensation | $201.00M | $161.00M | $136.10M | $150.90M | $185.00M | +24.8% |
| Change in working capital | -$670.00M | -$1.66B | -$3.67B | $1.21B | -$2.26B | +59.7% |
| Operating cash flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | +100.5% |
| Capital expenditure | -$6.21B | -$2.53B | -$2.97B | -$2.81B | -$1.80B | -145.7% |
| Investing cash flow | -$15.40B | -$3.92B | -$2.80B | -$2.98B | -$1.83B | -293.2% |
| Share buybacks | -$1.60B | -$2.36B | -$1.51B | -$708.30M | -$692.00M | +32.0% |
| Dividends paid | -$1.55B | -$1.55B | -$1.35B | -$1.35B | -$1.35B | +0.1% |
| Financing cash flow | $8.43B | -$3.47B | -$2.88B | $530.80M | -$1.25B | +342.8% |
| Free cash flow | $4.47B | $2.80B | $254.20M | $6.03B | $1.28B | +59.7% |
| End cash position | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | +69.4% |
Options analytics
Put / call volume
0.72
Call-heavy session
Put / call open interest
1.08
Positioning, not flow
Max pain
1,155.00
-0.2% from spot
ATM implied vol
45.0%
Nearest strike to spot
Skew (10% OTM)
+8.0%
Puts bid over calls
Call volume
5.16K
Contracts, this expiry
Put volume
3.69K
Contracts, this expiry
Heaviest call OI
1,620.00
811 contracts
Heaviest put OI
1,095.00
496 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 6.58 | 8.38 | +27.3% |
| Mar 2026 | 6.79 | 8.55 | +25.9% |
| Dec 2025 | 6.91 | 7.54 | +9.1% |
| Sep 2025 | 5.89 | 7.02 | +19.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 9.96 | 17 | $22.36B | +27.1% |
| Next quarter | 10.06 | 17 | $23.34B | +21.0% |
| Current year | 36.95 | 27 | $88.50B | +35.8% |
| Next year | 47.59 | 27 | $102.15B | +15.4% |
Analyst targets & ownership
Mean target$1,328.83
High target$1,600.00
Low target$930.00
Implied upside14.59%
Analyst count29
ConsensusBUY
Strong buy / Buy6 / 19
Hold3
Sell / Strong sell1 / 1
Held by insiders0.16%
Held by institutions85.31%
Institutions holding5.86K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1,163.61
-0.34% from price
SMA 20
1,152.58
+0.43% from price
SMA 50
1,174.93
-1.48% from price
SMA 100
1,153.99
+0.49% from price
SMA 200
1,074.84
+7.69% from price
EMA 12
1,157.82
+0.16% from price
EMA 26
1,161.74
-0.18% from price
EMA 50
1,161.81
-0.19% from price
RSI (14)
48.4
Neutral
MACD (12,26,9)
-3.92
Hist -0.07
ATR (14)
32.29
2.79% of price
Realised vol 30D
19.9%
Annualised
Bollinger upper
1,193.35
20, 2σ
Bollinger lower
1,111.82
20, 2σ
50 / 200 cross
Golden
1,174.93 vs 1,074.84
Trend bias
Above 200
+7.69%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.29
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
19.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-23.3%
Peak to trough
Max drawdown 5Y
-34.8%
Peak to trough
ATR 14
32.29
2.79% of price
Beta (reported)
0.45
5Y monthly, from filing
Short interest
Shares short
7.52M
Prior 6.56M
Change vs prior
+14.6%
Shorts adding
% of float
0.84%
Normal
% of shares out
0.84%
Against total outstanding
Days to cover
3.1
Liquid
Float
888.95M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 22, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Sep 18, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 10, 26 | HSBC | MAINTAINED | Reduce | Reduce |
| Aug 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 15, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 14, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 10, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$6.92 / yr
Forward yield0.61%
5-year avg yield0.77%
Payout ratio21.69%
Ex-dividend dateAug 14, 2026
Next pay dateSep 10, 2026
Last split2:1
Split dateOct 16, 1997
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Annual report of employee stock purchase
11-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-05-20
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-07
Periodic Financial Reports
10-Q · 2026-04-30
Proxy Statements
DFAN14A · 2026-03-31
Proxy Statements
DEF 14A · 2026-03-20
Headlines
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
Zacks · 5h ago
Lilly Stock Rises as $870 Million Gate Deal Adds One Target
GuruFocus.com · 6h ago
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
24/7 Wall St. · 9h ago
General Medicine Raises $120 Million to Build the Healthcare Store
PR Newswire · 11h ago
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 13h ago
Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis. There’s a Catch Investors Shouldn’t Miss
Insider Monkey · 13h ago
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief
The Wall Street Journal · 13h ago
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief
The Wall Street Journal · 13h ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.